Stephen Wanaski, Ph.D., is senior vice president of research and exploratory development at Evozyne, overseeing basic science, pharmacology and toxicology, clinical pharmacology, and scientific due diligence.

Dr. Wanaski is an experienced drug development leader with a track record in orphan drug development of small and large molecules from discovery through late-stage clinical studies and FDA approval.   He previously served as vice president of research and exploratory development at Castle Creek Pharmaceuticals and Marathon Pharmaceuticals, where he played a key role in the approval of a Duchenne muscular dystrophy therapy.

Earlier, Dr. Wanaski held senior R&D roles at NeuroTherapeutics Pharma and Ovation Pharmaceuticals, supporting multiple first-cycle NDA approvals. He began his career at oncology-focused NeoPharm and holds a bachelor’s degree from the University of Notre Dame and a Ph.D. in biochemistry from the University of Illinois at Urbana-Champaign.